RxElite, Inc. is a specialty pharmaceutical company that develops and markets generic prescription drug products in specialty generic markets. The company is headquartered in Eagle, Idaho and currently employs 47 full-time employees. The company went IPO on 2007-07-23. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The firm's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.
Follow-Up Questions
¿Cuál es el ratio P/E de RXElite Inc (RXEI)?
El ratio P/E de RXElite Inc es 0
¿Qué tal es el rendimiento del precio de la acción RXEI?
El precio actual de RXEI es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de RXElite Inc?
RXElite Inc pertenece a la industria N/A y el sector es N/A
¿Cuál es la capitalización bursátil de RXElite Inc?
La capitalización bursátil actual de RXElite Inc es $0
